The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 192.50
Bid: 190.00
Ask: 195.00
Change: 0.00 (0.00%)
Spread: 5.00 (2.632%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 192.50
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Clontarf raises GBP400,000; Faron jumps

Mon, 18th Mar 2024 10:05

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Faron Pharmaceuticals Ltd, up 29% at 180.00 pence, 12-month range 120.00p-370.00p. The drug discovery and development company provides further data from patients treated during the phase one part of the ongoing Bexmab trial that has moved into phase two for higher-risk myelodysplastic syndrome patients failed on previous hypomethylating agent. Chief Executive Markku Jalkanen says: "These data are really remarkable and confirm our belief that we may finally have a treatment for this underserved patient population. The data are strongly supportive that a registrational trial would be positive against any contemporary comparator when the final endpoint is survival. We eagerly await completion of the Phase 2 part of the BEXMAB study so we can take these data to the FDA as soon as possible."

----------

AIM - LOSERS

----------

Focusrite PLC, down 33% at 258.40p, 12-month range 245.00p-670.00p. The music and audio products firm expects revenue to be at least GBP155 million in the financial year ending August 31, down from GBP178.5 million in financial 2023. "[First half] performance has been impacted by similar factors across the group's geographic regions. The content creation market globally continues to struggle due to a number of macroeconomic issues. Content creation revenue in Asia has shown particular continued weakness with now 18 months of continuous decline, the largest negative impacts being in China and Japan, and no improvement is now assumed for the remainder of the year," Focusrite says.

----------

Clontarf Energy PLC, down 36% at 0.033p, 12-month range 0.032p-0.18p. The oil, gas and minerals explorer raises GBP400,000 through a placing of 1.14 billion shares priced at 0.035p each. The shares represent approximately 18% of the company's share capital. The net proceeds of the placing will be used to advance Clontarf's lithium projects in Bolivia, and neighbouring countries, as well as on petroleum projects in Ghana, Australia, and elsewhere, and for general working capital purposes.

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
8 Nov 2019 10:30

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

Read more
7 Nov 2019 17:59

Faron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress

Faron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress

Read more
1 Nov 2019 16:58

LONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week

LONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week

Read more
1 Nov 2019 15:32

Faron Pharmaceuticals Unable To Explain Significant Shares Price Surge

Faron Pharmaceuticals Unable To Explain Significant Shares Price Surge

Read more
9 Oct 2019 14:05

Faron Pharmaceuticals positive on feedback from 'Clevegen' monitoring committee

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced feedback from the 'MATINS' study data monitoring committee on Wednesday, from the ongoing dose escalation study from part 1 of the MATINS trial.

Read more
9 Oct 2019 09:18

Faron Pharmaceuticals To Test New Lower Dose In Clevegen Study

Faron Pharmaceuticals To Test New Lower Dose In Clevegen Study

Read more
2 Oct 2019 14:57

Faron Pharmaceuticals hits bump in road for Traumakine manufacturing

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Wednesday that, further to its update in its interim results in relation to the active pharmaceutical ingredient (API) manufacturing process for 'Traumakine', Rentschler Biopharma has sent Faron a letter in which it terminated the agreement concerning the API manufacturing.

Read more
2 Oct 2019 13:13

Manufacturer Ends Traumakine Agreement With Faron Pharmaceuticals

Manufacturer Ends Traumakine Agreement With Faron Pharmaceuticals

Read more
23 Sep 2019 11:37

Faron Pharmaceuticals Ends Traumakine Trial; Loss Narrows On Expenses

(Alliance News) - Faron Pharmaceuticals Oy on Monday said its loss narrowed considerably in the first half of 2019, after it cut back on research & development spending and opted to end a firm

Read more
16 Sep 2019 15:59

UK Earnings, Trading Statements Calendar - Next 7 Days

Tuesday 17 September JTCHalf Year ResultsStafflineHalf Year GroupHalf Year Year

Read more
27 Aug 2019 16:34

Faron Pharma raises ?2.3m to keep it going through the start of 2020

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has received valid acceptances and excess applications from qualifying shareholders for a total of 859,513 open offer shares, raising gross proceeds of around €1.01m (£0.92m) at the issue price of 106p per share and at the euro issue price of 119 cents per share, it announced on Tuesday.

Read more
27 Aug 2019 11:38

Faron Pharma Raises EUR2.5 Million; Now Has Working Capital To 2020

(Alliance News) - Faron Pharmaceuticals Oy on Tuesday said it has raised EUR2.5 million via share subscription and open offer.The company raised EUR1.0 million from the issue of 859,513 at

Read more
5 Aug 2019 12:26

Faron Pharmaceuticals To Raise EUR2.1 Million For Clevegen Development

(Alliance News) - Faron Pharmaceuticals Oy on Monday announced a EUR1.1 million subscription and EUR2.0 million open offer to fund the clinical development of cancer drug Clevegen.Shares in

Read more
12 Jul 2019 10:35

WINNERS & LOSERS SUMMARY: Thomas Cook Plunges On Rescue Deal Talks

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------BHP up 1.5%. The -

Read more
12 Jul 2019 10:20

Faron Pharma Pleased By MATINS Progress And Plans To Increase Capacity

(Alliance News) - Faron Pharmaceuticals Oy said on Friday its MATINS study of nine cancer patients is progressing well, and it is planning to expand the clinical trial to more countries.The

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.